Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.32 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CCND3 | P30281 | 1/20 | 0.31 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29781791 | 1.00 | CA12 (0.40) | CA12CA1CA9PREPTRPA1 | |
| SCHEMBL298834 | 0.88 | CA12 (0.40) | CA12CA1CA9PREPFGFR1 | |
| SCHEMBL628214 | 0.84 | PDPK1 (0.50) | CA12CA1CA9KDRPDPK1 | |
| SCHEMBL176760 | 0.80 | KDR (0.36) | TRPA1SCN5ASCN9ACHEK1KDR | |
| SCHEMBL31437119 | 0.79 | CA12 (0.40) | CA12CA1CA9PREPCDK4 | |
| SCHEMBL15792074 | 0.78 | ITK (0.47) | PDPK1ITKMAP2K4 | |
| SCHEMBL31327351 | 0.77 | — | — | |
| SCHEMBL24607104 | 0.75 | LRRK2 (0.32) | — | |
| SCHEMBL30540805 | 0.75 | LRRK2 (0.32) | — | |
| SCHEMBL27819676 | 0.74 | ELANE (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12297205-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-3925956-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240059702-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9732104-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| WO-2017136395-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170057993-A1 | Ether Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-3110423-A2 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2015130842-A9 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2015130842-A2 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | CA12 3449/4885CA1 4833/4885CA9 4389/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | CA12 3780/4885CA1 4118/4885CA9 2709/4885 |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | CA12 3432/4885CA1 4384/4885CA9 3510/4885 |
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | ZC3HAV1, ZC3HAV1L, IFNAR1 | CA12 3102/4885CA1 3802/4885CA9 1588/4885 |
| US-20170057993-A1 | Ether Compounds for Treatment of Medical Disorders | CFD, TFPI, F12 | CA12 3631/4885CA1 4805/4885CA9 4438/4885 |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | C9, C5, C1QBP | CA12 4667/4885CA1 4670/4885CA9 4089/4885 |
| US-11559515-B2 | Indole compounds and analogues thereof | C5, IDO1, IDO2 | CA12 2716/4885CA1 2970/4885CA9 2185/4885 |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, C9 | CA12 1306/4885CA1 3111/4885CA9 3418/4885 |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, C9 | CA12 1306/4885CA1 3111/4885CA9 3418/4885 |
| US-12297205-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | CA12 3780/4885CA1 4118/4885CA9 2709/4885 |
| US-20240059702-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CA12 3780/4885CA1 4118/4885CA9 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.